When this was written — On 31 August 2026. The figures are as at that date or earlier and have not been updated since.
The capital deluge
The rapid expansion of 4DMedical's (ASX:4DX) share register has provided ample fuel for short sellers, who have steadily built a double-digit position over the first half of 2026. The capital dilution began in earnest on 14 January 2026 when the company completed a massive $150 million institutional placement 1. Rather than sating the market's appetite for paper, this was followed just over two months later on 26 March 2026 by an additional $83 million placement to fund European expansion alongside CE Mark approval for its CTVQ software 23. While these raises bolstered the balance sheet, they also diluted existing holders and gave institutional short sellers a highly liquid target to borrow against. The sheer volume of new shares issued has structurally altered the trading dynamics of the stock, attracting a level of short interest that now dwarfs its peers. When a company issues over $230 million in new equity within a single quarter, it inevitably invites the attention of macro funds looking to hedge or outright short what they perceive as an over-hydrated register.
Red ink and sudden drops
The pressure on the stock intensified following the release of the half-year financial results on 27 February 2026. 4DMedical reported a statutory net loss of $153.86 million for H1 FY26 R4. While the report highlighted a $15 million minimum order commitment from Philips, the massive statutory loss dominated market attention and fuelled a deterioration in sentiment R4. Operating revenue for the half stood at just $2.9 million R4, highlighting a stark valuation gap that short sellers have been eager to exploit. This fundamental disconnect led to sharp daily sell-offs, most notably on 10 June 2026 when the share price plunged nearly 9% in a single session as short-seller activity intensified 5. A subsequent slide on 25 June 2026 further illustrated the vulnerability of the heavily diluted register to sudden bouts of selling pressure 6, as momentum traders and short sellers aligned to push the price lower.
The counter-offensive
Yet, the bearish thesis has run into a wall of insider conviction. On 19 June 2026, director Julian Sutton mounted a direct defence of the register, purchasing A$99,994.02 worth of shares on-market 78. On the same day, fellow director Lilian Bianchi exercised options, signalling a coordinated show of confidence by the board 910. This insider buying represents a significant financial commitment, with net director purchases over the last 90 days reaching A$99,994. It suggests that those closest to the technology believe the market is mispricing the company's commercial trajectory, particularly following recent clinical milestones. The contrast between the board's actions and the short positions highlights a classic battleground scenario: institutional shorts betting on structural dilution and high cash burn, versus insiders backing the technology's long-term commercial adoption. For retail investors, this insider buying provides a psychological anchor, suggesting that those with the most visibility see value where the shorts see vulnerability.
What the tape says
The data reveals a stark divergence between the short position and the actual price action. 4DMedical's short position currently sits at 12.36%, well above the peer healthcare sector average of 7.05%. This short position is not a static bet; it has risen 2.04 percentage points over the last 90 days, peaking at a high of 13.40%. Yet, despite this growing short pressure, the share price has remained remarkably resilient, up 12.0% over the last month and 9.6% over the last three months, though it remains slightly down at -2.7% over a six-month horizon. The 30-day price-to-short correlation stands at -0.683, indicating that while short sellers have continued to press their bets, they have failed to drive the stock down sustainably.
With the T+4 ASIC reporting delay, the 12.36% short figure reflects positions held late last week, meaning the battle is still actively playing out. Short sellers face a difficult exit if the stock continues to defy gravity, as a 12% short position in a tightly held medical technology stock can take weeks to orderly cover. If the short sellers are forced to buy back their positions to limit losses, the resulting squeeze could catch many off-guard, especially given the lack of liquid supply following the recent insider lock-ups.
The contrast between the board's actions and the short positions highlights a classic battleground scenario.
- 2026-01-14A$150M placement completed[ref-1]
- 2026-02-27H1 FY26 net loss of $153.86M reported[ref-4]
- 2026-03-26A$83M placement for European expansion[ref-2]
- 2026-06-19Director Julian Sutton buys A$100k on-market[ref-7]